Shanghai Yidian Pharmaceutical Technology Development Co. Ltd. has disclosed peptidyl nitrile compounds acting as cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of cancer, infections, diabetes, respiratory, metabolic, cardiovascular, cerebrovascular and autoimmune disease, among others.